NCT04849715 - A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | Biotech Hunter

Timeline

Start Date

March 11, 2022

Primary Completion Date

August 15, 2030

Study Completion Date

July 7, 2034

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

parsaclisib

parsaclisib will be administered orally once daily.

DRUG

rituximab

rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.

DRUG

bendamustine

bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.

DRUG

Placebo

placebo will be administered orally once daily